TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00360152

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fine needle aspiration biopsy (FNAB)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fine needle aspiration biopsy (FNAB)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel Lymph Node Biopsy
Study: NCT03693014

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: (27 Gy over 3 fractions)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab
Description: The checkpoint inhibitor that the patient was already receiving should be continued according to the standard schedule and dose of administration as determined by the treating physician. Immune Checkpoint Inhibitors include Ipilimumab (Melanoma) Nivolumab (Melanoma, Renal, NSCLC), Pembrolizumab (Melanoma, NSCLC), Atezolizumab (Bladder)
Study: NCT04484012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO
Study: NCT04303403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Taken orally twice daily
Study: NCT04382079

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: honey
Description: Since the patient received radiation therapy, Taiwan Longan Honey has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: propolis
Description: Since the patient received radiation therapy, Taiwan green propolis has been used for a total of eight weeks.~Understand the changes of oral mucositis and various symptoms during this period
Study: NCT02473263

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: Ceftriaxone 2g IV will be infused in the first 60 minutes, for non nosocomial severe septic syndrome

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin tazobactam
Description: Piperacillin/tazobactam 4g IV will be infused in the first 60 minutes, for nosocomial severe septic syndrome

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Norepinephrine will be infused after failure of hemodynamic optimization using vascular fluid loading

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone 100mg IV will be infused after failure of hemodynamic optimization using norepinephrine with at least 1.5mg/h
Study: NCT01433003

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma Exchange
Description: Plasma exchange is a blood purification technique that removes plasma from the blood and replaces it with donor plasma.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasma Exchange
Description: Plasma exchange is a blood purification technique that removes plasma from the blood and replaces it with donor plasma.
Study: NCT00067873

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Study: NCT00300495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Description: Perioperative orally administered

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control arm, standard care
Description: Control
Study: NCT03250520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum acetylacetonate (1% wt) supported by sol-gel technology functionalized titania
Description: Sol-gel process Pt(acac)2- F-TiO2 nanostructured material with antitumoral activity used as an alternative in the treatment of cancer tumors. The biocatalysts were prepared by the sol-gel route using the complex Pt(acac)2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum acetylacetonate (1% wt) supported by sol-gel technology functionalized titania
Description: Sol-gel process Pt(acac)2- F-TiO2 nanostructured material with antitumoral activity used as an alternative in the treatment of cancer tumors. The biocatalysts were prepared by the sol-gel route using the complex Pt(acac)2.
Study: NCT00720707

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF+ADM+EMD
Description: using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) with enamel matrix derivatives (EMD).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF+ADM
Description: using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) without enamel matrix derivatives (EMD) for root coverage procedures.
Study: NCT04886830

Intervention type: PROCEDURE
Intervention: laparoscopic appendectomy using a single endoloop for appendiceal stump closure
Description: laparoscopic appendectomy using a single endoloop for appendiceal stump closure before resecting the appendix

Intervention type: PROCEDURE
Intervention: laparoscopic appendectomy using two endoloops for appendiceal stump closure
Description: laparoscopic appendectomy using a two endoloops for appendiceal stump closure before resecting the appendix
Study: NCT03996421

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutritional iron (14 mg) supplement in form of ferrous fumarate
Description: nutritional iron (14 mg) supplement in form of ferrous fumarate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ferrous fumarate + 15 g GOS
Description: nutritional iron (14 mg) supplement in form of ferrous fumarate with addition of prebiotics (15 g GOS)
Study: NCT00360152

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel Lymph Node Biopsy
Study: NCT01176942

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic bacterium Bifidobacterium lactis
Description: Probiotic placebo controlled intervention
Study: NCT04364971

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: singleradius and multiradius total knee arthroplasty
Description: singleradius and multiradius total knee arthroplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: singleradius and multiradius total knee arthroplasty
Description: singleradius and multiradius total knee arthroplasty
Study: NCT04606966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Horseback Riding
Description: Horse therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Barn Activity
Description: Horsemanship group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid
Description: Ground and riding activities
Study: NCT01300065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental- Soflens
Description: A new pair of lenses will be worn each day while the subject is in the study

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed - Soflens
Description: A new pair of lenses will be worn each day while the subject is in the study.
Study: NCT03896932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: minipooled- Intravenous immunoglobulin(MP-IVIG)
Description: The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.
Study: NCT01163877

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fe-57 orally, Fe-58 intravenously
Description: Subjects will receive a test drink containing 3 mg Fe-57 in the form of labelled FeSO4 followed by 1 ml of an aqueous solution containing 50 μg Fe-58 as iron citrate.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fe-57 orally, Fe-58 intravenously
Description: Subjects will receive a test drink containing 3 mg Fe-57 in the form of labelled FeSO4 followed by 1 ml of an aqueous solution containing 50 μg Fe-58 as iron citrate.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fe-57 orally, Fe-58 intravenously
Description: Subjects will receive a test drink containing 3 mg Fe-57 in the form of labelled FeSO4 followed by 1 ml of an aqueous solution containing 50 μg Fe-58 as iron citrate.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fe-57 orally, Fe-58 intravenously
Description: Subjects will receive a test drink containing 3 mg Fe-57 in the form of labelled FeSO4 followed by 1 ml of an aqueous solution containing 50 μg Fe-58 as iron citrate.
Study: NCT01783873

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™)
Description: At Visit 1: Patients are selected and they will receive a metacholine challenge test during and outside of work. After randomization, patients undergo a standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™) to either an wheat flour allergen extract or didecyldimethylammonium chloride or placebo. Each bronchial challenge test is followed by blood sampling at different time points and induced sputum. The immediate bronchial response and late bronchial response will be recorded.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™)
Description: At Visit 1: Patients are selected and they will receive a metacholine challenge test during and outside of work. After randomization, patients undergo a standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™) to either an wheat flour allergen extract or didecyldimethylammonium chloride or placebo. Each bronchial challenge test is followed by blood sampling at different time points and induced sputum. The immediate bronchial response and late bronchial response will be recorded.
Study: NCT02452658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Changed menu
Description: After making the hypothetical choice, participants will be exposed to a menu with changed calorie and price labels, as well as several other changes.
Study: NCT01176942

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic bacterium Bifidobacterium lactis
Description: Probiotic placebo controlled intervention
Study: NCT04886830

Intervention type: PROCEDURE
Intervention: laparoscopic appendectomy using a clip for appendiceal stump closure
Description: laparoscopic appendectomy using an endoclip for appendiceal stump closure before resecting the appendix
Study: NCT06694038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needle Knife Fistulotomy
Description: Biliary access using needle knife fistulotomy technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard biliary cannulation
Description: standard biliary cannulation
Study: NCT01511237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine, zidovudine, lamivudine
Description: * Mothers: One NVP 200 mg tablet at onset of labor with continuation of HAART for four weeks postpartum~* Newborn: AZT+3TC+ NVP for 2 weeks, followed by AZT+3TC for 2 weeks:~  * NVP syrup 2 mg/kg every 24 hours for seven days, followed by NVP syrup 4 mg/kg every 24 hours for seven days. Newborns less than 2500 g will be administered 2mg/kg NVP syrup at each intake~ * AZT syrup 4 mg/ kg will be given every 12 hours for four weeks (preterm infants less than 30 weeks will be administered 2 mg/kg every 12 hours; preterm 30-35 weeks will receive 2 mg/kg every 12 hours for the first 2 weeks, increased to 3 mg/kg for the next 2 weeks).~ * 3TC syrup 2 mg/kg every 12 hours for four weeks.
Study: NCT01791296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
Study: NCT01801969

Intervention type: OTHER
Intervention: Rehabilitation service
Description: * Centralized/ decentralized hospital based rehabilitation defined as hospital based rehabilitation in a single or in multiple locations, respectively.~* Size of the municipality responsible for providing rehabilitation services after discharge from hospital
Study: NCT02609906

Intervention type: DEVICE
Group type: OTHER
Intervention: PhilosTM with augmentation (Depuy-Synthes)
Description: All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.~Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the angle stable plate fixation system PhilosTM with augmentation (Depuy-Synthes).
Study: NCT04159727

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stool and blood analysis
Description: High throughput sequencing and quantitative PCR

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stool and blood analysis
Description: High throughput sequencing and quantitative PCR
Study: NCT04272853

Intervention type: OTHER
Intervention: Interview
Description: Compilation of the interview concerning: demographic data, sports practice, habits on sleep, sexual habits, perception of the relationship between sexual habits and sleep, perception of the relationship between sexual habits and sports practice.
Study: NCT02609906

Intervention type: DEVICE
Group type: OTHER
Intervention: MultiLoc®-Nail (Depuy-Synthes)
Description: All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.~Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the multiplanar proximal humeral nail MultiLoc® (Depuy-Synthes).
Study: NCT02563210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: airway resistance measurement
Description: assessment of airway resistance
Study: NCT02571855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 (hydrochloride salt)
Description: Hard-gelatin capsules (strength: 5 mg and 25 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 (hydrochloride salt)
Description: Hard-gelatin capsules (strength: 5 mg and 25 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 (free base)
Description: Soft capsules (strength: 25 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching the ACT-541468 formulations

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching the ACT-541468 formulations

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching the ACT-541468 formulations
Study: NCT01245049

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix PolioTM
Description: Single dose, intramuscular administration.
Study: NCT00791128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GI Liner
Description: Medical device placed endoscopically in the duodenum, nutritional counseling
Study: NCT02599389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-coated balloons

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-coated balloons

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer Laser
Study: NCT00722059

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Tomosynthesis
Description: 3D breast imaging
Study: NCT01245049

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RepevaxTM
Description: Single dose, intramuscular administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PriorixTM
Description: Single dose, intramuscular or subcutaneous administration.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PriorixTM
Description: Single dose, intramuscular or subcutaneous administration.
Study: NCT01319461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyalgan
Description: Patients will receive intraarticular injection of 20mg /2ml /syringe Hyalgan® once a week for 5 consecutive weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sterile normal saline
Description: Patients will receive intraarticular injection of sterile normal saline once a week for 5 consecutive weeks.
Study: NCT04632030

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco power wall size and tobacco products displayed
Description: The intervention varies the size of the tobacco power wall and number of tobacco products displayed on it.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco power wall size and tobacco products displayed
Description: The intervention varies the size of the tobacco power wall and number of tobacco products displayed on it.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco power wall size and tobacco products displayed
Description: The intervention varies the size of the tobacco power wall and number of tobacco products displayed on it.
Study: NCT03556878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitted Transdiagnostic Sleep and Circadian intervention
Description: Fitted TranS-C is an adapted version is designed to improve the fit with community needs and resources.
Study: NCT03475043

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Auditory training: temporal cues
Description: Behavioral training for 6-9 hours in listening to specific characteristics of acoustic signals. Listeners receive correct-answer feedback on each trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory training: temporal cues
Description: Behavioral training for 6-9 hours in listening to specific characteristics of acoustic signals. Listeners receive correct-answer feedback on each trial.
Study: NCT03383081

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose mesenchymal stem cells
Description: Human umbilical cord mesenchymal stem cells (SCLnow 19#): group A, 1 \* 10\^7 cells (5ml);

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose mesenchymal stem cells
Description: Human umbilical cord mesenchymal stem cells (SCLnow 19#): group B, 2 \* 10\^7 cells (5ml)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraarticular injection
Description: Intraarticular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#) with different dose group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraarticular injection
Description: Intraarticular injection with human umbilical cord mesenchymal stem cells (SCLnow 19#) with different dose group
Study: NCT00527878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Double blinded, randomized placebo controlled crossover study. Patients received 12 months of placebo and 12 months of treatment medication (ranitidine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranitidine
Description: Double blinded, randomized placebo controlled crossover study. Patients received 12 months of placebo and 12 months of treatment medication (ranitidine).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04495478

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramucirumab - IV
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - IV
Description: Administered IV.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramucirumab - SC
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab - SC
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab - SC
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab - SC
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - SC
Description: Administered SC.
Study: NCT00969085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin (Turmeric)
Description: Chew then swallow 2 sticks per day for up to 6 months.~2 sticks = 1 packet of curcumin = 8 grams

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Quality of life (QOL) questionnaires completed on Day 1, Weeks 2, 4, 8, 12, 16, 20, and at end of treatment visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photos
Description: Photos of up to 6 selected skin lesion(s) and half-body photos taken on Day 1, Weeks 2, 4, 12, and at end of treatment visit.
Study: NCT03971045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will be treated with pembrolizumab administered as an intravenous infusion at 200 mg in 21-day treatment cycles and oral cyclophosphamide (CTX) 50 mg per day in metronomic administration as a 21 days cycle